Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B

INCYTE CORP

2021-FY EPS reported $4.27 revenue$2,986,267,000

Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).
GAAP net income $563.9M includes $569M tax benefit from valuation allowance release; non-GAAP diluted EPS $0.10.
Opzelura launch: ~19,000 patients treated in Q4; vitiligo sNDA under Priority Review with PDUFA April 18, 2022.
Parsaclisib NDA withdrawn for FL/MZL/MCL in U.S.; baricitinib SLE Phase 3 discontinued; baricitinib AD sNDA faces potential CRL.
2022 guidance: Jakafi $2.3-2.4B, other heme/onc $210-240M; GAAP R&D $1.55-1.59B, SG&A $950M-1B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.